ArticleCancer2025
Burden of female-specific cancers in China from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021.
Article in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Patient preferences for managing chronic breast cancer-related lymphedema in China: evidence from a discrete choice experiment.BMC health services research · 2026Article
- The quality and reliability of endometrial cancer-related videos on social short video platforms: a cross-sectional study.BMC women's health · 2026Article
- Mesenchymal stem cell therapy for premature ovarian insufficiency: progress and challenges.Journal of ovarian research · 2026Review
- Burden and temporal trends of female-specific cancers in China: A systematic analysis of the 2023 global burden of disease study.PloS one · 2026Article
- Trust buffers price-related barriers to HPV vaccination among female college students: a cross-sectional study in China based on the 3C model.Frontiers in public health · 2026Article
- Global trends and future projections of cervical cancer burden: an integrated analysis of GBD 2021, UN population and WHO HPV vaccination data.Frontiers in public health · 2026Article
- The global cancer crisis: a review of growing burden, deepening inequality and initiatives for prevention and early detection.Ecancermedicalscience · 2026Review
- Global burden of ovarian cancer attributable to high BMI, 1990-2021: spatiotemporal trends, risk factors, frontier analysis, and projections to 2036 based on GBD 2021 study.Journal of ovarian research · 2025Article
- Machine learning and SHAP value interpretation for predicting the response to neoadjuvant chemotherapy and long-term clinical outcomes in Chinese female breast cancer.Annals of medicine · 2025Article
- Under-recognized risk factors and low perceived breast cancer risk among rural women in South-central China: A multisite cross-sectional study.Asia-Pacific journal of oncology nursing · 2025Article
- Article
- MSPO: A machine learning hyperparameter optimization method for enhanced breast cancer image classification.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundBreast cancer and reproductive system cancers remain significant public health threats for Chinese women. This study aimed to evaluate the latest epidemiological patterns and trends of four female-specific cancers in China.
methodsThe year- and age-specific estimates of the incidence, mortality, and disability-adjusted life-years (DALYs) associated with breast, cervical, ovarian, and uterine cancers in China from 1990 to 2021 were generated from the Global Burden of Disease, Injuries, and Risk Factors 2021 study. The epidemiological characteristics were analyzed with age-period-cohort models. A Bayesian age-period-cohort model was applied to forecast disease burden from 2022 to 2050.
resultsIn 2021, China reported 385.84 thousand (95% uncertainty interval [UI], 294.10-489.01 thousand) incident cases of female breast cancer, followed by cervical cancer (132.79 thousand [95% UI, 95.96-172.60 thousand]), uterine cancer (72.02 thousand [95% UI, 53.31-100.00 thousand]), and ovarian cancer (41.24 thousand [95% UI, 30.30-54.55 thousand]). Breast cancer ranked as the primary cause of cancer-related deaths, followed by cervical cancer. The age-specific incidence rate for breast, cervical, ovarian, and uterine cancers are projected to occur in the age groups 60-64 years, 55-59 years, 65-69 years, and 60-64 years, respectively. Breast, ovarian, and uterine cancer cases are projected to rise by 2050, which will exceed those recorded in 2021.
conclusionsVarious inequities have been identified across four types of cancers affecting women, which underscores the need for tailored national cancer control strategies. Emphasis should be placed on primary prevention and screening for breast and cervical cancers, whereas efforts for uterine and ovarian cancers should focus on implementing early diagnosis and treatment measures. PLAIN LANGUAGE SUMMARY: This study examines the burdens and trends of breast, cervical, ovarian, and uterine cancers among Chinese women from 1990 to 2021. In 2021, breast cancer emerged as the most prevalent, followed by cervical, uterine, and ovarian cancers, with breast cancer also exhibiting the highest mortality rate. The age groups projected to exhibit the highest incidence rates for breast, cervical, ovarian, and uterine cancers are 60-64 years, 55-59 years, 65-69 years, and 60-64 years, respectively. Projections indicate that by 2050, the incidence of breast, ovarian, and uterine cancers will surpass 2021 levels, which underscores the necessity for targeted prevention, early detection, and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.